Immediate Impact
3 from Science/Nature 74 standout
Citing Papers
Pancreatic cancer
2025 Standout
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Works of Jean‐Philippe Metges being referenced
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.
2019
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jean‐Philippe Metges | 1126 | 790 | 687 | 702 | 112 | 2.1k | |
| Gabriela Studer | 849 | 1233 | 795 | 739 | 112 | 2.8k | |
| Riccardo Ragona | 674 | 1293 | 844 | 628 | 127 | 2.6k | |
| Jeffrey Meyer | 600 | 755 | 552 | 541 | 122 | 2.3k | |
| Falk Roeder | 972 | 1458 | 662 | 391 | 111 | 2.4k | |
| Nicolas Aide | 657 | 911 | 430 | 1534 | 105 | 2.7k | |
| Masashi Wakabayashi | 1321 | 1775 | 774 | 476 | 130 | 3.0k | |
| Jee Suk Chang | 713 | 523 | 530 | 561 | 169 | 1.9k | |
| Martin N.J.M. Wasser | 460 | 577 | 841 | 564 | 88 | 2.3k | |
| Daisuke Sakai | 1278 | 913 | 460 | 346 | 119 | 2.2k | |
| Quan‐Yong Luo | 680 | 417 | 553 | 659 | 121 | 2.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...